The dysfunction of nk cells in patients with type 2 diabetes and colon cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 61, Issue 3, 2013, Pages 245-253

  Piątkiewicz, Paweł ^a   Miłek, Tomasz ^a   Bernat Karpińska, Małgorzata ^a   Ohams, Monika ^a   Czech, Anna ^a   Ciostek, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Colon cancer; Diabetes; NK cells

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INCRETIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CELL COUNT; CELL FUNCTION; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DIET; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOPHENOTYPING; MALE; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; RADIOIMMUNOASSAY;

EID: 84878018709     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-013-0222-5     Document Type: Article

References (56)

1. Armitage P (1971) Statistical methods in medical research, 3rd edn. Blackwell Scientific Publications, Oxford
2. Atchison EA, Gridley G, Carreon JD et al (2011) Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 128:635-643
3. Berster JM, Göke B (2008) Type 2 diabetes mellitus as risk factor for colon cancer. Arch Physiol Biochem 114:84-98
4. Burt RW, Barthel JS, Dunn KB et al (2010) NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 8:8-61
5. Buzzai M, Jones RG, Amaravadi RK et al (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752
6. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
7. Czech A, Piatkiewicz P, Tatoń J (2009) Cellular glucose transport and glucotransporter 4 expression as a therapeutic target: clinical and experimental studies. Arch Immunol Ther Exp 57:467-473
8. Feng YH, Velazquez-Torres G, Gully C et al (2011) The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 15:825-836
9. Flood A, Strayer L, Schairer C et al (2010) Diabetes and risk of incident colorectal cancer in a prospective cohort of women. Cancer Causes Control 21:1277-1284
10. Gallagher EJ, LeRoith D (2011) Diabetes, cancer and metformin: connections of metabolism and cell proliferation. Ann NY Acad Sci 1243:54-68
11. Gonzalez-Angulo AM, Meric-Bernstam F (2010) Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16:1695-1700
12. Hannet I, Erkeller-Yurksel F, Deneys V et al (1992) Lymphocyte populations as a function of age. Immunol Today 13:215-218
13. Held W, Kijima M, Angelov G et al (2011) The function of natural killer cells: education, reminders and some good memories. Curr Opin Immunol 23:228-233
14. Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15:548-555
15. Herberman RB, Ortaldo JR (1981) Natural killer cells: their role in defenses against disease. Science 214:24-30
16. Herberman RB, Nunn ME, Lavrin DH (1975a) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 16:216-229
17. Herberman RB, Nunn ME, Holden HT et al (1975b) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16:230-239
18. Hercend T, Takvorian T, Nowill A et al (1986) Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 67:722-728
19. Hjartåker A, Langseth H, Weiderpass E (2008) Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 630:72-93
20. Inoue M, Iwasaki M, Otani T et al (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871-1877
21. Iovino F, Meraviglia S, Spina M et al (2011) Immunotherapy targeting colon cancer stem cells. Immunotherapy 3:97-106
22. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S et al (2011) IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol 186:3401-3409
23. Jenab M, Riboli E, Cleveland RJ et al (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121:368-376
24. Johann S, Blümel G, Lipp M et al (1995) A versatile flow cytometry-based assay for the determination of short- and long-term natural killer cell activity. J Immunol Methods 185:209-216
25. Kaaks R, Toniolo P, Akhmedkhanov A et al (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592-1600
26. Kahi CJ, Imperiale TF, Juliar BE et al (2009) Effect of screening colonoscopy on colorectal cancer incidence. Clin Gastroenterol Hepatol 7:770-775
27. Kane KL, Ashton FA, Schmitz JL et al (1996) Determination of natural killer cell function by flow cytometry. Clin Diagn Lab Immunol 3:295-300
28. Keever CA, Pekle K, Gazzola MV et al (1989) Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. J Immunol 143:3241-3249
29. Lanier LL, Phillips JH, Hackett J Jr et al (1986) Natural killer cells: definition of a cell type rather than a function. J Immunol 137:2735-2739
30. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679-1687
31. LeRoith D, Novosyadlyy R, Gallagher EJ et al (2008) Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 116(Suppl 1):S4-S6
32. Libby G, Donnelly LA, Donnan PT et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625
33. Ma J, Giovannucci E, Pollak M et al (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546-553
34. Migliorati G, Cannarile L, Herberman RB et al (1989) Effect of various cytokines and growth factors on the interleukin-2- dependent in vitro differentiation of natural killer cells from bone marrow. Nat Immun Cell Growth Regul 8:48-55
35. Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23:255-259
36. Moretta L, Bottino C, Pende D et al (2005) Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 100:7-13
37. Moutschen MP, Scheen AJ, Lefebvre PJ (1992) Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabetes Metab 18:187-201
38. Ozer H, Strelkauskas AJ, Callery RT et al (1979) The functional dissection of human peripheral null cells with respect to antibody-dependent cytotoxicity and natural killing. Eur J Immunol 9:112-118
39. Pia̧tkiewicz P, Czech A (2011) Glucose metabolism disorders and the risk of cancer. Arch Immunol Ther Exp 59:215-230
40. Pia̧tkiewicz P, Czech A, Pia̧tkiewicz A (2010) The pathophysiology of the NK (natural killer) cells. Med Metabol 15:71-76
41. Pross HF (1986) The involvement of natural killer cells in human malignant disease. In: Lotzova E, Herberman RB (eds) Immunobiology of natural killer cells, vol 2. CRC, Boca Raton, p 11
42. Rex DK, Johnson DA, Anderson JC et al (2009) American Collage of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol 104:739-750
43. Ritz J, Schmidt RE, Michon J et al (1988) Characterization of functional surface structures on human natural killer cells. Adv Immunol 42:181-211
44. Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76:2421-2438
45. Roder JC, Haliotis T, Klein M et al (1980) A new immunodeficiency disorder in humans involving NK cells. Nature 284:553-555
46. Rooney CM, Wimperis JZ, Brenner MK et al (1986) Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol 62:413-420
47. Rosenberg EB, Herberman RB, Levine PH et al (1972) Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer 9:648-658
48. Sakakibara M, Kanto T, Hayakawa M et al (2011) Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother 60:1565-1575
49. Spooren PF, Vermes I, Soons JW (1993) Similar alterations of lymphocyte subpopulations in type I and type II diabetes. Neth J Med 42:163-167
50. Sullivan JL, Byron KS, Brewster FE et al (1980) Deficient natural killer cell activity in X-linked lymphoproliferative syndrome. Science 210:543-545
51. Timonen T, Ortaldo JR, Herberman RB (1981) Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 153:569-582
52. Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187-376
53. Tseng CH (2012) Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol 167:409-416
54. Van den Brink MR, Boggs SS, Herberman RB et al (1990) The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures. J Exp Med 172:303-313
55. Wei EK, Ma J, Pollak MN et al (2005) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomark Prev 14:850-8555
56. Zheng C, Feng J, Lu D et al (2011) A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity. PLoS ONE 6:e21146